Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/01/2023 | 199.73% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
08/04/2023 | 226.98% | Chardan Capital | → $12 | Reiterates | Buy → Buy |
06/06/2023 | 199.73% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
05/08/2023 | 226.98% | Chardan Capital | → $12 | Reiterates | → Buy |
03/31/2023 | 199.73% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
03/24/2023 | 199.73% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
03/10/2023 | 199.73% | JonesTrading | → $11 | Initiates Coverage On | → Buy |
03/03/2023 | 172.48% | Piper Sandler | $8 → $10 | Maintains | Overweight |
12/08/2022 | 199.73% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
09/23/2022 | 226.98% | Chardan Capital | → $12 | Initiates Coverage On | → Buy |
05/24/2022 | 8.99% | Goldman Sachs | $7 → $4 | Maintains | Neutral |
05/23/2022 | 90.74% | Piper Sandler | $30 → $7 | Maintains | Overweight |
08/24/2021 | 880.93% | Wedbush | → $36 | Initiates Coverage On | → Outperform |
08/24/2021 | 717.44% | Jefferies | → $30 | Initiates Coverage On | → Buy |
08/24/2021 | 717.44% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
08/24/2021 | 499.46% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
What is the target price for Omega Therapeutics (OMGA)?
The latest price target for Omega Therapeutics (NASDAQ: OMGA) was reported by HC Wainwright & Co. on September 1, 2023. The analyst firm set a price target for $11.00 expecting OMGA to rise to within 12 months (a possible 199.73% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Omega Therapeutics (OMGA)?
The latest analyst rating for Omega Therapeutics (NASDAQ: OMGA) was provided by HC Wainwright & Co., and Omega Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Omega Therapeutics (OMGA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Omega Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Omega Therapeutics was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
Is the Analyst Rating Omega Therapeutics (OMGA) correct?
While ratings are subjective and will change, the latest Omega Therapeutics (OMGA) rating was a reiterated with a price target of $0.00 to $11.00. The current price Omega Therapeutics (OMGA) is trading at is $3.67, which is within the analyst's predicted range.